| Drug Name: | Eptifibatide (188627-80-7) |
|---|---|
| PubChem ID: | 77906395 |
| SMILES: | C1C[C@H]2C(=O)N[C@H](CSSCCC(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N |
| InchiKey: | CZKPOZZJODAYPZ-RTJMFUJLSA-N |
| Therapeutic Category: | Hematologic Agents, Platelet Aggregation Inhibitors |
| Molecular Weight (dalton) | : | 831.979 |
| LogP | : | -2.0544 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 11 |
| Hydrogen Bond Donor Count | : | 10 |
| Total Polar Surface Area | : | 326.39 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Antiplatelet Effect | Integrin Alpha-IIb precursor (P08514) | Antiplatelet effect [ ADR Type 1 ] | Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. |
| Antiplatelet Effect | Integrin beta-3 precursor (P05106) | Antiplatelet effect [ ADR Type 1 ] | Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category